<sup>18</sup>F-FDG PET/CT Staging of Head and Neck Cancer: Interobserver Agreement and Accuracy-Results from Multicenter ACRIN 6685 Clinical Trial.
other
Where this comes from
- Record sourced from PubMed, PMID 35552246.
- Also identified by DOI 10.2967/jnumed.122.263902 and PMC identifier 9730921.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To our knowledge, no prior multicenter clinical trial has reported interobserver agreement of <sup>18</sup>F-FDG PET/CT scans for staging of clinical N0 neck in head and neck cancer. <b>Methods:</b> A total of 287 participants were recruited. For visual analysis, positive nodal uptake of <sup>18</sup>F-FDG was defined as uptake visually greater than activity seen in the blood pool. <b>Results:</b> The negative predictive value of the <sup>18</sup>F-FDG PET/CT for N0 clinical neck was 86% or above for visual assessment (95% CI, 86%-88%) for the 2 central readers and above 90% (95% CI, 90%-95%) for SUV<sub>max</sub> for central reads and site reads dichotomized at the optimal cutoff value of 1.8 and the prespecified cutoff value of 3.5, respectively. The κ coefficients between the 2 expert readers and between central reads and site reads varied between 0.53 and 0.78. <b>Conclusion:</b> The NPV of the <sup>18</sup>F-FDG PET/CT for N0 clinical neck was 86% or above for visual assessment and above 90% for SUV<sub>max</sub> cut points of 1.8 and 3.5 with moderate to substantial agreements.
Medical subject headings
- Fluorodeoxyglucose F18
- Head and Neck Neoplasms